Guideline Summary for Hyperthyroidism Management

First‑Line Pharmacologic Therapy

• Methimazole is the preferred initial antithyroid drug for virtually all adults with newly diagnosed hyperthyroidism, with the goal of achieving euthyroidism within 4 weeks. 1
• Initiate methimazole at 0.4–0.8 mg/kg/day (approximately 10–40 mg daily) for rapid control of thyroid hormone synthesis. 2
• Add a beta‑adrenergic blocker in patients > 60 years, with resting heart rate > 90 bpm, known cardiovascular disease, or any symptomatic hyperthyroid presentation to control tachycardia and adrenergic symptoms. 3
• Obtain baseline complete blood count with differential and liver function tests (bilirubin and transaminases) before starting methimazole. 1
• Instruct patients to stop methimazole immediately and contact a clinician if fever, sore throat, oral ulcers (suggesting agranulocytosis), jaundice, dark urine, pale stools, severe abdominal pain (suggesting hepatotoxicity), or severe rash develop. 1
• Propylthiouracil should be reserved exclusively for first‑trimester pregnancy, thyroid storm, or minor methimazole reactions when the patient declines radioactive iodine or surgery, because PTU carries a higher risk of severe hepatotoxicity, including fatal hepatic necrosis. 3

Monitoring During Antithyroid‑Drug Therapy

• Week 4: Measure free T4 and total T3; adjust methimazole dose accordingly. 1
• Every 4–8 weeks: Repeat thyroid‑function tests until euthyroid on the minimal effective dose. 1
• Every 2–3 months after euthyroidism: Continue monitoring free T4 and TSH. 1
• Routine white‑blood‑cell counts are not required; obtain a differential only during febrile illness or pharyngitis because agranulocytosis can develop rapidly with initially normal counts. 1
• Assess liver function only if the patient develops symptoms suggestive of hepatotoxicity (e.g., nausea, fatigue, abdominal pain, jaundice). 1

Definitive Treatment Options (after euthyroidism is achieved)

1. Continued Antithyroid‑Drug Therapy (12–18 months)

• Continue methimazole for 12–18 months, then taper or discontinue if TSH is within the normal range; this approach offers a potential cure without lifelong hormone replacement, with an approximate 50 % remission rate. 1
• Measure TSH‑receptor antibodies (TRAb) before stopping therapy; elevated TRAb (> 3–6 U/L) predicts a ≥ 50 % relapse risk, whereas low/negative TRAb is associated with sustained remission in roughly 50 % of patients. 1
• After discontinuation, monitor thyroid function every 1–3 months for 6–12 months to detect early relapse. 1
• Predictors of higher relapse risk include smoking, male sex, age < 40 years, severe initial hyperthyroidism (free T4 > 3 × upper limit of normal), large goiter (> 80 mL), and persistently elevated TRAb. 1
• For patients who relapse or have high‑risk features, long‑term methimazole (5–10 years) is feasible, reducing recurrence to ≈ 15 % (vs ≈ 50 % with short‑term therapy); requires monitoring every 2–3 months and patient acceptance of indefinite medication use. 1

2. Radioactive Iodine (RAI) Therapy

• Absolute contraindications: pregnancy, breastfeeding, or planning pregnancy within 4–6 months; also inability to comply with radiation‑safety precautions. 4
• Pre‑treatment preparation: If free T4 is 2–3 × upper limit of normal or the patient is markedly symptomatic, pretreat with methimazole and beta‑blockers; discontinue methimazole 3–7 days before RAI to avoid reducing efficacy. 4
• Provide written radiation‑safety instructions to the patient before therapy. 1

Post‑RAI Follow‑up

• 1–2 months: Check free T4 and total T3. 1
• Every 4–6 weeks while the patient remains thyrotoxic: repeat thyroid‑function tests. 1
• At 3 months: If response is minimal, consider retreatment. 1
• At 6 months: Persistent hyperthyroidism warrants repeat RAI. 1
• Lifelong: Perform annual thyroid‑function testing once euthyroidism or hypothyroidism is achieved. 1

3. Near‑Total or Total Thyroidectomy

• Near‑total or total thyroidectomy provides very rapid definitive disease control and avoids radiation exposure. 1
• Best suited for large goiters (≥ 80 g) or symptomatic compression, women planning pregnancy within < 4–6 months, coexisting suspicious/malignant nodules, and patients refusing radiation and antithyroid drugs. 1
• Pre‑operative preparation: render the patient euthyroid with methimazole ± beta‑blockers and stop methimazole on the day of surgery. 1
• Administer potassium iodide (e.g., 5–7 drops of Lugol’s solution or 1–2 drops of saturated potassium iodide solution three times daily) for 10 days before surgery to reduce thyroid vascularity. 1
• Lifelong annual monitoring of thyroid function is recommended after total or near‑total thyroidectomy. 1

Special Populations

Pregnancy

• First trimester: Switch from methimazole to propylthiouracil immediately upon a positive pregnancy test because methimazole is linked to congenital malformations (e.g., aplasia cutis, choanal/esophageal atresia). 5
• Second and third trimesters: Switch back to methimazole to avoid PTU‑related hepatotoxicity risk. 5
• Target thyroid levels: Keep free T4 at or slightly above the upper limit of the non‑pregnant reference range (or total T4 ≈ 1.5 × upper limit) while maintaining suppressed TSH. 5
• Monitoring: Check thyroid function monthly and adjust antithyroid‑drug dose as needed. 5
• TRAb measurement: Assess TRAb at 22–26 weeks gestation; values > 3 × upper limit of normal indicate high risk of fetal/neonatal thyrotoxicosis and prompt intensified fetal monitoring. 5
• Thyroidectomy during pregnancy: If surgery is required, perform it in the second trimester when feasible. 5

Graves’ Ophthalmopathy

• In mild active ophthalmopathy without risk factors, all three definitive treatments (RAI, methimazole, thyroidectomy) are equally acceptable. 6
• In mild active ophthalmopathy with risk factors (especially smoking), concurrent corticosteroid prophylaxis should be given if RAI is chosen. 6
• In moderate‑to‑severe or sight‑threatening active ophthalmopathy, treat with methimazole or surgery; avoid RAI unless combined with high‑dose glucocorticoids. 6
• Promptly maintain euthyroidism to prevent progression of ophthalmopathy. 6
• Advise patients to stop smoking and refer them to a structured smoking‑cessation program, as smoking is a major risk factor for ophthalmopathy progression. 6

Critical Pitfalls to Avoid

• Do not use propylthiouracil as first‑line therapy except in first‑trimester pregnancy, thyroid storm, or methimazole intolerance due to severe hepatotoxicity risk. 3
• Do not perform routine white‑blood‑cell monitoring; obtain a differential only during febrile illness. 1
• Do not administer radioactive iodine to women planning pregnancy within 4–6 months. 4
• Do not discontinue methimazole before 12 months unless definitive therapy is planned; premature cessation almost invariably leads to relapse. 1
• Do not rely on TSH alone to decide on antithyroid‑drug discontinuation, because TSH may remain suppressed for weeks to months after free T4 normalizes; interpret TSH together with free T4 and T3. 1
• After resolution of hyperthyroidism, TSH may stay suppressed for ≥ 1 month; always consider concurrent free T4 and T3 values when assessing disease status. 1

Management of Primary Hyperthyroidism

Initial Antithyroid Drug Therapy

• The American College of Endocrinology and the American Association of Clinical Endocrinologists recommend methimazole as the first‑line antithyroid medication for virtually all adults with newly diagnosed primary hyperthyroidism, with the goal of achieving euthyroidism within approximately four weeks. 7
• Initiate meth dose at 10–40 mg daily (≈0.4–0.8 mg/kg). Use 10–20 mg for mild‑moderate disease and 30–40 mg when free T₄ is ≥2–3 × the upper limit of normal. 7
• Obtain a complete blood count with differential and liver‑function tests (bilirubin and transaminases) before starting methimazole. 7
• Add a β‑blocker immediately in patients > 60 years, resting heart rate > 90 bpm, with co‑existing cardiovascular disease, or any symptomatic patient to control tachycardia and adrenergic symptoms. [8][9]
• Instruct patients to stop methimazole and contact a clinician promptly if they develop fever, sore throat, oral ulcers, jaundice, dark urine, pale stools, severe abdominal pain, or a serious rash—signs suggestive of agranulocytosis or hepatotoxicity. 7
• Propylthiouracil should be reserved exclusively for the first trimester of pregnancy, thyroid storm, or minor methimazole intolerance when radioactive iodine or surgery is declined, because of its higher risk of severe hepatotoxicity. 7

Monitoring During Antithyroid Drug Therapy

• At week 4, measure free T₄ and total T₃ and adjust the methimazole dose accordingly. 7
• Repeat thyroid‑function tests every 4–8 weeks until euthyroidism is achieved with the lowest effective dose. 7
• After euthyroidism, monitor free T₄ and TSH every 2–3 months. 7
• Routine leukocyte counts are not required; obtain a differential only during febrile illness or pharyngitis because agranulocytosis can develop rapidly with initially normal counts. 7
• Check liver‑function tests only if the patient develops symptoms suggestive of hepatotoxicity (e.g., nausea, fatigue, abdominal pain, jaundice). 7
• Recognize that TSH may remain suppressed for ≥1 month after free T₄ normalizes; interpret TSH together with free T₄ and T₃. 7

Definitive Therapy Options

1. Prolonged Antithyroid Drug Course (12–18 months)

• Continuing methimazole for 12–18 months, then tapering/discontinuing when TSH is within the reference range, offers a potential cure without lifelong hormone replacement; remission occurs in roughly 50 % of patients. 10
• Measure TSH‑receptor antibodies (TRAb) before stopping therapy: a high TRAb (>3–6 U/L) predicts ≥50 % relapse risk, whereas a low/negative TRAb is associated with sustained remission in about 50 % of patients. 10
• Predictors of higher relapse risk include smoking, male sex, age < 40 years, severe initial hyperthyroidism (free T₄ > 3 × ULN), large goiter (>80 mL), and persistently elevated TRAb. 10
• For patients who relapse or possess high‑risk features, long‑term methimazole (5–10 years) reduces recurrence to ≈15 % versus ≈50 % with short‑term therapy; this approach requires monitoring every 2–3 months and patient acceptance of indefinite medication. 10

2. Radioactive Iodine (RAI) Therapy

• Absolute contraindications to RAI are pregnancy, lactation, planning pregnancy within 4–6 months, or inability to adhere to radiation‑safety precautions. [8][9]
• If free T₄ is 2–3 × ULN or the patient is markedly symptomatic, pre‑treat with methimazole and a β‑blocker; discontinue methimazole 3–7 days before RAI to avoid reducing treatment efficacy. [8][9]
• Administer a single RAI dose (typically 10–15 mCi) sufficient to induce hypothyroidism. [8][9]
• Provide written radiation‑safety instructions before therapy. [8][9]
• Post‑RAI follow‑up:
  
  • 1–2 months – check free T₄ and total T₃. 8
  • Every 4–6 weeks while still thyrotoxic – repeat thyroid tests. 8
  • 3 months – consider retreatment if response is minimal. [7][8]
  • 6 months – repeat RAI if hyperthyroidism persists. [7][8]
  • Thereafter – perform annual thyroid‑function testing once euthyroidism or hypothyroidism is achieved. [7][8]

3. Total or Near‑Total Thyroidectomy

• Total or near‑total thyroidectomy provides rapid, definitive disease control and avoids radiation exposure. [10][11]
• Indications include large goiters (≥80 g), compressive symptoms, women planning pregnancy within <4–6 months, co‑existing suspicious or malignant nodules, and patients who decline radiation or antithyroid drugs. [10][11]
• Pre‑operative preparation: achieve euthyroidism with methimazole ± β‑blocker and stop methimazole on the day of surgery. [10][11]
• Administer potassium iodide (5–7 drops Lugol solution or 1–2 drops saturated potassium iodide three times daily) for 10 days pre‑operatively to reduce thyroid vascularity. [10][11]
• Surgery should be performed by a high‑volume thyroid surgeon (≥30 thyroidectomies/year, ideally >100) to minimize complications. 11
• Lifelong annual thyroid‑function monitoring is recommended after total or near‑total thyroidectomy. 11

Critical Pitfalls to Avoid

• Do not use propylthiouracil as first‑line therapy except in the first trimester of pregnancy, thyroid storm, or methimazole intolerance because of severe hepatotoxicity risk. 7
• Do not perform routine leukocyte monitoring; obtain a differential only during febrile illness. 7
• Do not administer radioactive iodine to women planning pregnancy within 4–6 months. [8][9]
• Do not discontinue methimazole before 12 months unless definitive therapy is planned; premature cessation almost invariably leads to relapse. 10
• Do not rely solely on TSH to decide antithyroid drug discontinuation, as TSH may remain suppressed for weeks to months after free T₄ normalizes; interpret TSH together with free T₄ and T₃. 7
• Do not perform thyroidectomy without a high‑volume surgeon, as complication rates rise markedly with low‑volume operators. 11

Definitive Treatment of Hyperthyroidism – Evidence‑Based Recommendations

Radioactive Iodine (RAI) Therapy

• Absolute contraindications – RAI should not be used in patients who are pregnant, breastfeeding, planning pregnancy within 4–6 months, have coexisting thyroid cancer, or cannot adhere to radiation‑safety guidelines. (American College of Endocrinology & American Association of Clinical Endocrinologists) 12
• Pre‑treatment preparation for high‑risk patients – In elderly patients or those with cardiovascular disease or severe hyperthyroidism due to toxic multinodular goiter or toxic adenoma, initiate beta‑adrenergic blockade (and consider methimazole) before RAI and continue until euthyroidism is achieved. (American College of Endocrinology & American Association of Clinical Endocrinologists) 12
• Post‑RAI follow‑up – If hyperthyroidism persists at 6 months after the initial dose, a repeat RAI treatment is recommended. (American College of Endocrinology & American Association of Clinical Endocrinologists) 12

Thyroidectomy

• Pre‑operative euthyroidism – Achieve a euthyroid state with methimazole (± beta‑blockers) before surgery and discontinue methimazole on the day of the operation. (American College of Endocrinology & American Association of Clinical Endocrinologists) 12
• Surgeon volume requirement – The procedure should be performed by a high‑volume thyroid surgeon (≥ 30 thyroidectomies per year, ideally > 100) to minimize peri‑operative complications. (American College of Endocrinology & American Association of Clinical Endocrinologists) 12
• Post‑operative calcium management – Measure serum calcium or intact parathyroid hormone after surgery for toxic multinodular goiter and provide oral calcium and calcitriol supplementation based on the results. (American College of Endocrinology & American Association of Clinical Endocrinologists) 13
• Thyroid hormone replacement dosing – Start levothyroxine at 0.8 µg per lb (≈ 1.7 µg/kg) daily; elderly patients may require a modestly lower dose. (American College of Endocrinology & American Association of Clinical Endocrinologists) 13
• TSH monitoring after surgery – Check TSH every 1–2 months until a stable level is achieved, then at least annually thereafter. (American College of Endocrinology & American Association of Clinical Endocrinologists) 13
• Timing of surgery during pregnancy – If thyroidectomy is indicated in a pregnant patient, schedule the operation in the second trimester when feasible. (American College of Endocrinology & American Association of Clinical Endocrinologists) 12

Thyroid Storm Management

• Multimodal intensive‑care approach – Treat thyroid storm with a combination of beta‑adrenergic blockade, antithyroid drugs, inorganic iodide, high‑dose corticosteroids, aggressive cooling (acetaminophen and cooling blankets), aggressive fluid resuscitation, respiratory support, and continuous monitoring in an intensive‑care setting. (American College of Endocrinology & American Association of Clinical Endocrinologists) 13

Safety Considerations

• Pregnancy‑related restriction on RAI – Do not administer radioactive iodine to women who are planning pregnancy within 4–6 months. (American College of Endocrinology & American Association of Clinical Endocrinologists) 12

Guidelines for Methimazole Management in Hyperthyroidism

Biochemical Targets and Routine Monitoring

• Target hormone levels: A total T3 within the normal range (≈80–200 ng/dL) confirms biochemical euthyroidism while maintaining free T4 in the upper‑normal zone and a mildly suppressed TSH during active therapy. [American College of Endocrinology & American Association of Clinical Endocrinology] [14]
• Laboratory follow‑up: Check TSH, free T4, and total T3 every 2–3 months while the patient is in the maintenance phase of antithyroid drug therapy. [American College of Endocrinology & American Association of Clinical Endocrinology] [Annales d’endocrinologie] 14, 15
• Complete blood count: Routine CBC is not required; obtain a differential white‑cell count only if the patient develops fever, sore throat, oral ulcers, or other infection signs, because agranulocytosis can appear abruptly and routine testing does not provide early detection. [American College of Endocrinology & American Association of Clinical Endocrinology] 14
• Liver function tests: Perform LFTs only when symptoms suggest hepatotoxicity (e.g., jaundice, dark urine, pale stools, severe abdominal pain, persistent nausea or fatigue). [American College of Endocrinology & American Association of Clinical Endocrinology] 14

Duration of Therapy and Discontinuation Planning

• Total treatment length: Continue methimazole for 12–18 months from therapy initiation to maximize the chance of sustained remission; stopping earlier almost invariably leads to relapse. [American College of Endocrinology & American Association of Clinical Endocrinology] 14
• TRAb testing before stopping: Measure TSH‑receptor antibodies (TRAb). An elevated TRAb (>3–6 U/L) predicts a ≥50 % relapse risk, whereas a low/negative TRAb is associated with ≈50 % chance of lasting remission. [American College of Endocrinology & American Association of Clinical Endocrinology] 14
• TSH criteria for taper/discontinuation: Taper or cease methimazole only after TSH has returned to the full reference range (≈0.4–4.0 µIU/mL). A mildly suppressed TSH (e.g., ~0.5 µIU/mL) is acceptable during therapy but should normalize before drug withdrawal. [American College of Endocrinology & American Association of Clinical Endocrinology] 14
• Post‑withdrawal monitoring: After stopping methimazole, re‑check TSH and free T4 every 1–3 months for 6–12 months to detect early relapse (suppressed TSH with elevated free T4 or free T3). [American College of Endocrinology & American Association of Clinical Endocrinology] 14

Relapse Management and Definitive Treatment Options

• Preferred definitive therapies after relapse: If hyperthyroidism recurs after a 12–18 month course, radioactive iodine (RAI) or total/near‑total thyroidectomy are the first‑line options; a second short methimazole course is unlikely to achieve durable remission. [American College of Endocrinology & American Association of Clinical Endocrinology] 14, 16
• Radioactive iodine details: A single dose of 10–15 mCi typically induces hypothyroidism within 4–8 weeks. Contraindications include pregnancy, breastfeeding, or planning pregnancy within the next 4–6 months. [American College of Endocrinology & American Association of Clinical Endocrinology] 14, 16
• Thyroidectomy considerations: Near‑total or total thyroidectomy offers rapid definitive control and avoids radiation. It should be performed by a high‑volume surgeon (≥30 thyroidectomies/year, ideally >100) to minimize complications. [American College of Endocrinology & American Association of Clinical Endocrinology] 14, 16

Critical Safety Alerts

• Immediate drug discontinuation: Instruct patients to stop methimazole immediately and seek urgent medical attention if they develop any of the following: fever, sore throat, oral ulcers (suggesting agranulocytosis), or signs of hepatotoxicity such as jaundice, dark urine, pale stools, or severe abdominal pain. [American College of Endocrinology & American Association of Clinical Endocrinology] 14
• Avoid premature cessation: Do not discontinue methimazole before completing 12 months unless definitive therapy (RAI or surgery) is already planned; early cessation almost guarantees relapse. [American College of Endocrinology & American Association of Clinical Endocrinology] 14
• Interpretation of TSH: Do not rely on TSH alone for dose adjustment or discontinuation decisions, because TSH may remain suppressed for weeks to months after free T4 normalizes; always interpret TSH together with free T4 and total T3. [American College of Endocrinology & American Association of Clinical Endocrinology] 14

Guideline Recommendations for Management of the Hyperthyroid Phase

Immediate Symptomatic Control

• The American College of Endocrinology and the American Association of Clinical Endocrinologists advise that beta‑adrenergic blockade be started immediately in any patient with symptomatic hyperthyroidism, in individuals older than 60 years, in those with a resting heart rate >90 bpm, or in anyone with cardiovascular disease, while concurrently initiating methimazole. [17][18]
• Propranolol 40–80 mg orally every 6–8 hours (total 160–320 mg/day) is the preferred beta‑blocker because it also inhibits peripheral conversion of T4 to T3, providing rapid relief of tachycardia, tremor, anxiety, and other adrenergic symptoms. 17
• Beta‑blockade is mandatory for patients >60 years, those with resting HR > 90 bpm, those with cardiovascular comorbidities (e.g., atrial fibrillation, heart failure, coronary artery disease), and for all symptomatic individuals regardless of age. [17][18]

Antithyroid Drug Therapy

• Methimazole is recommended as the first‑line antithyroid medication for virtually all adults with hyperthyroidism, initiated at 10–40 mg once daily according to disease severity. 17
• In severe hyperthyroidism (free T4 ≥ 2–3 × the upper limit of normal) or in highly symptomatic patients, an initial dose of 30–40 mg daily of methimazole is advised. [17][18]

Use of Propylthiouracil (PTU)

• PTU should be reserved for three specific situations: first‑trimester pregnancy, thyroid storm, or when a patient experiences minor methimazole reactions and declines radioactive iodine or surgery. 17

Critical Patient Education

• Patients should be instructed to discontinue methimazole immediately and seek urgent medical care if they develop fever, sore throat, oral ulcers (suggesting agranulocytosis), jaundice, dark urine, pale stools, severe abdominal pain (suggesting hepatotoxicity), or a severe rash. 17

Management of Destructive Thyroiditis

• In painless (post‑partum, silent, or drug‑induced) thyroiditis, beta‑blockers provide symptomatic relief, but antithyroid drugs are ineffective because new hormone synthesis is already suppressed. [19][20]
• For subacute thyroiditis with mild symptoms, treatment consists of beta‑blockers and NSAIDs; if symptoms are moderate‑to‑severe or refractory, add corticosteroids (prednisone 40 mg daily for 2–4 weeks, then taper over 2–3 months). [19][20]
• In amiodarone‑induced thyrotoxicosis type 2 (destructive), prednisone 40 mg daily for 2–4 weeks followed by a gradual taper is recommended; when the distinction between type 1 and type 2 is unclear, combine methimazole 40 mg daily with prednisone until the patient stabilizes. [19][20]

Thyroid Storm (Multimodal Intensive‑Care Approach)

• A thyroid storm (Burch‑Wartofsky score ≥ 45) mandates immediate ICU admission and a multimodal regimen: beta‑adrenergic blockade, antithyroid drugs, inorganic iodide administered ≥ 1 hour after antithyroid drugs, high‑dose corticosteroids (hydrocortisone 100 mg IV every 8 h or dexamethasone 2 mg IV every 6 h), aggressive cooling with acetaminophen and cooling blankets (avoid aspirin), volume resuscitation, and respiratory support. 21

Common Pitfalls to Avoid

• Do not use PTU as first‑line therapy except in the three situations listed above, because of its higher risk of severe hepatotoxicity. 17
• Do not delay initiation of beta‑blocker therapy in elderly or cardiovascular patients; prompt treatment helps prevent arrhythmias and heart failure. 17
• Do not administer inorganic iodide before antithyroid drugs in thyroid storm, as this can exacerbate thyrotoxicosis by providing substrate for new hormone synthesis. 21

Evidence‑Based Recommendations for Managing Hyperthyroidism in Non‑Pregnant Adults

Initial Pharmacologic Management

• Methimazole dosing: Initiate 30–40 mg daily when the free T4 level is ≥ 2–3 × the upper limit of normal or the patient is markedly symptomatic. (American College of Endocrinology & American Association of Clinical Endocrinologists) 22
• Propylthiouracil (PTU) restriction: Reserve PTU exclusively for first‑trimester pregnancy, thyroid storm, or minor methimazole intolerance when the patient declines radioactive iodine or surgery, because PTU carries a higher risk of severe hepatotoxicity, including fatal hepatic necrosis. (American College of Endocrinology & American Association of Clinical Endocrinologists) 23
• Beta‑adrenergic blockade: Add a beta‑blocker immediately in patients > 60 years, resting heart rate > 90 bpm, known cardiovascular disease, or any symptomatic hyperthyroid patient to control adrenergic symptoms. (American College of Endocrinology & American Association of Clinical Endocrinologists) 22

Definitive Treatment Options (after euthyroidism is achieved)

Antithyroid‑Drug Therapy (12–18 months)

• Three equally acceptable definitive options: Continued antithyroid‑drug therapy, radioactive iodine (RAI), or near‑total/total thyroidectomy may be offered once euthyroidism is attained, with the choice guided by patient values and clinical factors. (American College of Endocrinology & American Association of Clinical Endocrinologists) 22

Radioactive Iodine (RAI)

• Patient selection for RAI: Best suited for patients of advanced age, those with significant comorbidities, prior neck surgery or scarring, small goiter size, or when access to a high‑volume thyroid surgeon is unavailable. (American College of Endocrinology & American Association of Clinical Endocrinologists) 24, 25
• Absolute contraindications to RAI: Pregnancy, breastfeeding, planning pregnancy within 4–6 months, coexisting thyroid cancer, or inability to comply with radiation‑safety precautions. (American College of Endocrinology & American Association of Clinical Endocrinologists) 22, 24, 25
• Pre‑treatment preparation: If free T4 is 2–3 × ULN or the patient is markedly symptomatic, pretreat with methimazole and a beta‑blocker before administering RAI. (American College of Endocrinology & American Association of Clinical Endocrinologists) 22

Near‑Total or Total Thyroidectomy

• Indications for surgery: Large goiters (≥ 80 g) or symptomatic compression, women planning pregnancy within 4–6 months, coexisting suspicious or malignant nodules, patients refusing radiation or antithyroid drugs, substernal/retrosternal extension, or need for rapid correction of thyrotoxicosis. (American College of Endocrinology & American Association of Clinical Endocrinologists) 22, 24, 25
• Surgical expertise requirement: Procedure should be performed by a high‑volume thyroid surgeon (≥ 30 thyroidectomies / year, ideally > 100) to keep permanent hypoparathyroidism < 2 % and recurrent laryngeal nerve injury < 2 %. (American College of Endocrinology & American Association of Clinical Endocrinologists) 24

Special Considerations

• Mild active Graves’ ophthalmopathy without risk factors: All three definitive treatments (RAI, methimazole, thyroidectomy) are equally acceptable. (American College of Endocrinology & American Association of Clinical Endocrinologists) 23
• Toxic multinodular goiter or toxic adenoma – RAI preference: RAI is favored for older patients, those with significant comorbidities, small goiters, or when a high‑volume surgeon is not accessible. (American College of Endocrinology & American Association of Clinical Endocrinologists) 24, 25
• Toxic multinodular goiter or toxic adenoma – Surgical preference: Surgery is preferred for large goiters (> 80 g), compressive symptoms, substernal extension, or coexisting hyperparathyroidism requiring operation. (American College of Endocrinology & American Association of Clinical Endocrinologists) 24, 25
• Beta‑blockade before RAI in high‑risk patients: Elderly patients, those with cardiovascular disease, or severe hyperthyroidism should receive beta‑blockers prior to RAI and until euthyroidism is achieved. (American College of Endocrinology & American Association of Clinical Endocrinologists) 25

Critical Pitfalls to Avoid

• Do not use PTU as first‑line therapy except in first‑trimester pregnancy, thyroid storm, or methimazole intolerance due to its severe hepatotoxicity risk. (American College of Endocrinology & American Association of Clinical Endocrinologists) 23
• Do not administer RAI to women planning pregnancy within 4–6 months. (American College of Endocrinology & American Association of Clinical Endocrinologists) 22, 24, 25
• Do not perform thyroidectomy without a high‑volume surgeon, as complication rates increase markedly with low‑volume operators. (American College of Endocrinology & American Association of Clinical Endocrinologists) 24